Document:

Exhibit 10.9

 

Execution Version

 

Date: August 27, 2021

 

 

AIPHARMA ASIA LIMITED

 

as Chargor

 

and

 

ADITXT, INC.

as Lender

 

 

 

FLOATING CHARGE

 

 

 

 

 

 

Bird & Bird

6/F, The Annex, Central Plaza

18 Harbour Road

Hong Kong

T +852 2248 6000

F +852 2248 6011

twobirds.com

Ref: WONC/

 

    

     

    

 

TABLE OF CONTENTS

 

	Clause	 	Headings	 	Page
	 	 	 	 	 
	1.	 	DEFINITIONS AND CONSTRUCTION	 	1
	 	 	 	 	 
	2.	 	COVENANTS TO PAY	 	4
	 	 	 	 	 
	3.	 	Security	 	4
	 	 	 	 	 
	4.	 	Crystallisation of Floating
    Charge	 	5
	 	 	 	 	 
	5.	 	FURTHER ASSURANCE	 	6
	 	 	 	 	 
	6.	 	GENERAL UNDERTAKINGS WITH
    RESPECT TO the Charged Assets	 	6
	 	 	 	 	 
	7.	 	UNDERTAKINGS WITH RESPECT
    TO the Charged Assets	 	7
	 	 	 	 	 
	8.	 	RIGHTS OF THE Lender	 	7
	 	 	 	 	 
	9.	 	EXONERATION	 	9
	 	 	 	 	 
	10.	 	APPOINTMENT OF RECEIVER	 	10
	 	 	 	 	 
	11.	 	RECEIVER’S POWERS	 	10
	 	 	 	 	 
	12.	 	PROTECTION OF PURCHASER	 	11
	 	 	 	 	 
	13.	 	POWER OF ATTORNEY AND DELEGATION	 	11
	 	 	 	 	 
	14.	 	Application Of Monies Received
    Under This Deed	 	12
	 	 	 	 	 
	15.	 	RELEASE OF SECURITY	 	12
	 	 	 	 	 
	16.	 	AMOUNTS PAYABLE	 	13
	 	 	 	 	 
	17.	 	MISCELLANEOUS	 	14
	 	 	 	 	 
	18.	 	calculations and certificates	 	16
	 	 	 	 	 
	19.	 	NOTICES	 	16
	 	 	 	 	 
	20.	 	counterparts	 	16
	 	 	 	 	 
	21.	 	ENTIRE AGREEMENT	 	16
	 	 	 	 	 
	22.	 	governing LAW	 	17
	 	 	 	 	 
	23.	 	Waiver of immunities	 	17
	 	 	 	 	 
	24.	 	dispute resolution	 	17
	 	 	 	 	 
	25.	 	contracts (rights of third
    parties) ordinance	 	18
	 	 	 	 	 
	26.	 	Punctual Performance	 	18
	 	 	 	 	 
	Schedule
    1 Receiver’s Powers	 	19

 

    

     

    

 

THIS
DEED is made on _________________ 2021

 

BETWEEN:

 

		(1)	AiPharma Asia Limited, a company incorporated in Hong Kong with registration number 2989727 and
having its registered office at Rooms 05-15, 13A/F., South Tower, World Finance Centre, Kowloon, Hong Kong (the “Chargor”);
and

 

		(2)	ADITXT, INC., a Delaware corporation (the “Lender”).

 

WHEREAS:

 

		(A)	The Chargor is entering into this Deed in connection with the Loan Documents (as defined below).

 

		(B)	The board of directors of the Chargor is satisfied that entering into this Deed is for the purposes and
to the benefit of the Chargor.

 

		(C)	The Lender and the Chargor intend this Deed to take effect as a deed of the Chargor (notwithstanding that
the Lender may have executed it under hand only).

 

IT IS AGREED as follows:

 

		1.	DEFINITIONS AND CONSTRUCTION

 

		1.1	Definitions

 

Terms defined in the Secured Credit
Agreement (as defined below) shall, unless otherwise defined in this Deed, or unless a contrary intention appears, bear the same meaning
when used in this Deed and the following terms shall have the following meanings:

 

“Affiliate”
has the meaning given in the Secured Credit Agreement.

 

“Borrower” means
any borrower under the Secured Credit Agreement.

 

“Business Day” means
a day on which commercial banks are generally open for business in Hong Kong.

 

“Charged Assets”
means the Receivables from time to time mortgaged, charged or assigned pursuant to Clause 3 (Security).

 

“Collateral Documents”
has the meaning given in the Secured Credit Agreement.

 

“Companies Ordinance”
means the Companies Ordinance (Cap. 622) of the Laws of Hong Kong.

 

“CPO” means the Conveyancing
and Property Ordinance (Cap. 219) of the Laws of Hong Kong.

 

“Event of Default”
has the meaning specified in Article VII of the Secured Credit Agreement.

 

    1

     

    

 

“Hong Kong”
means the Hong Kong Special Administrative Region of the People’s Republic of China.

 

“Loan” has the meaning
given in the Secured Credit Agreement.

 

“Loan Documents”
means, collectively, the Secured Credit Agreement, the Collateral Documents, all promissory notes, guarantees and any other documents
or instruments entered into in connection with the Secured Credit Agreement.

 

“Party”
means a party to this Deed.

 

“Receivables”
means all present and future book debts, receivables and monetary claims due or owing to the Chargor. 

 

“Receiver”
means any person appointed by the Lender to be a receiver or receiver and manager of the property subject to the Security created by this
Deed or any part thereof.

 

“Secured
Credit Agreement” means the secured credit agreement made between AIPHARMA HOLDINGS LIMITED, AIPHARMA GLOBAL HOLDINGS LLC, the
Chargor and the Lender, dated on or about the date of this Deed.

 

“Secured
Obligations” means all of the obligations owing to or expressed to be owing to the Lender by the Borrowers or any of them under
or pursuant to the Loan Documents or any of them, whether present or future, actual or contingent (and whether incurred alone or jointly
and whether as principal or surety or in some other capacity), and including without limitation any such obligation in respect of any
further advance or financial accommodation from time to time made available under any Loan Document.

 

“Security”
means any mortgage, charge, pledge, lien, assignment or other security interest securing any obligation of any person or any other agreement
or arrangement having similar effect.

 

“Security Period”
means the period from the date of this Deed until the date on which all of the Secured Obligations (whether actual or contingent) have
been irrevocably and unconditionally paid and discharged in full.

 

		1.2	Construction

 

		(a)	Unless a contrary indication appears, any reference in this Deed to:

 

		(i)	the singular includes the plural and vice versa;

 

		(ii)	the “Lender” and the “Chargor” shall be construed so as to include its
successors in title, permitted assigns and permitted transferees;

 

		(iii)	“assets” includes present and future properties, revenues and rights of every description;

 

		(iv)	a “regulation” includes any regulation, rule, official directive, request or guideline
(whether or not having the force of law) of any governmental, intergovernmental or supranational body, agency, department or regulatory,
self-regulatory or other authority or organisation;

 

    2

     

    

 

		(v)	a provision of law is a reference to that provision as amended or re-enacted;

 

		(vi)	a Clause or a Schedule is a reference to a clause of or schedule to this Deed;

 

		(vii)	this Deed shall be construed as references also to any separate or independent stipulation or agreement
contained in it;

 

		(viii)	a reference to an agreement (including the Secured Credit Agreement and each other Loan Document) shall
be construed as a reference to such agreement as the same may have been modified, extended, amended, varied or supplemented or novated
from time to time;

 

		(ix)	any form of property or asset (including a Charged Assets) shall include a reference to all or any part
of that property or asset; and

 

		(x)	the word “including” shall be construed as “including, without limitation”.

 

		(b)	Clause and Schedule headings are for ease of reference only.

 

		(c)	The words “other”, “or otherwise” and “whatsoever”
shall not be construed ejusdem generis or be construed as any limitation upon the generality of any preceding words or matters specifically
referred to.

 

		1.3	Effect as a Deed

 

This Deed is intended to take effect
as a deed notwithstanding that the Lender may have executed it under hand only.

 

		1.4	Inconsistency and no prohibition

 

		(a)	In the event of any inconsistency arising between any of the provisions of this Deed and the Secured Credit
Agreement, the provisions of the Secured Credit Agreement shall prevail.

 

		(b)	For the avoidance of doubt, the terms of this Deed shall not operate or be construed so as to prohibit
or restrict any transaction, matter or other step not prohibited by a Loan Document and the Lender shall promptly enter into such documentation
and/or take such other action as is required by the relevant Chargor (acting reasonably) in order to facilitate any such transaction,
matter or other step, including by way of executing any confirmation, consent to dealing, release or other similar or equivalent document,
provided that any costs and expenses incurred by the Lender entering into such documentation and/or taking such other action at the request
of the relevant Chargor, pursuant to this Clause 1.4(b) shall be for the account of the relevant Chargor.

 

		(c)	Notwithstanding any other provision of this Deed at all times prior to an Event of Default and unless
otherwise expressly contemplated under this Deed, the Lender confirms that each Chargor shall be free to deal with the Charged Assets
in the course of its business and in any other way not prohibited under the Loan Documents.

 

    3

     

    

 

		2.	COVENANTS TO PAY

 

		2.1	Nature

 

All Security created or made by or
pursuant to this Deed are created or made:

 

		(a)	in favour of the Lender; and

 

		(b)	as continuing security for the full and punctual payment and discharge of the Secured Obligations.

 

		2.2	Covenant to Pay Secured Obligations

 

The Chargor shall on demand of the
Lender discharge each of the Secured Obligations and pay to the Lender when due and payable each sum now or hereafter owing, due or incurred
by any Borrower in respect of the Secured Obligations.

 

		2.3	Potential Invalidity

 

Neither the covenant to pay in Clause
2.2 (Covenant to Pay Secured Obligations) nor the Security created by this Deed shall extend to or include any liability or sum
which would, but for this Clause 2.3, cause such covenant, obligation or Security to be unlawful under any applicable law.

 

		3.	Security

 

		3.1	The Chargor charges as legal and/or beneficial owner in favour of the
Lender, as security for the payment and discharge of the Secured Obligations, by way of first floating charge, all of its present and
future rights, title, benefit and interest in and to the Charged Assets provided that the Chargor may deal with the Charged Assets in
the ordinary course of its business until the Security created by this Deed becomes enforceable or this floating charge is converted into
a fixed charge pursuant to Clauses 4.1 or 4.2.

 

		3.2	The floating charge created by the Chargor pursuant to Clause 3.1 shall
rank in priority to any subsequently created Security over any of the Charged Assets.

 

		3.3	Unless the context otherwise requires, a reference to a Charged Asset
includes: 

 

		(a)	any part of that Charged Asset; and

 

		(b)	the proceeds of sale of that Charged Asset.

 

    4

     

    

 

		4.	Crystallisation of Floating Charge

 

		4.1	Crystallisation: By Notice

 

The
Lender may at any time by notice in writing to the Chargor convert any floating charge created under this Deed with immediate effect into
a fixed charge as regards any property or assets specified in the notice if: 

 

		(a)	an Event of Default has occurred; or

 

		(b)	the Lender is reasonably of the view that any asset charged under the floating charge created under this
Deed is in danger of being seized or sold under any form of distress, attachment, execution or other legal process or is otherwise in
jeopardy; or

 

		(c)	the Lender reasonably considers, that it is necessary in order to protect the priority of the Security
created under this Deed.

 

		4.2	Crystallisation: Automatic

 

Notwithstanding
Clause ‎4.1 (Crystallisation: By Notice) and without prejudice
to any law which may have a similar effect, any floating charge created by this Deed will automatically be converted (without notice)
with immediate effect into a fixed charge as regards all the assets subject to the floating charge if: 

 

		(a)	the members of that Chargor convene a meeting for the purposes of considering any resolution for its winding-up,
dissolution, or a compromise, assignment or arrangement with any creditor (except as permitted or not prohibited by the Loan Documents
or with the prior consent of the Lender); or

 

		(b)	that Chargor creates, or purports to create, Security (except as permitted or not prohibited by the Loan
Documents or with the prior consent of the Lender) on or over any asset which is subject to the floating charge created under this Deed;

 

		(c)	any third party takes any step with a view to levying distress, attachment, execution or other legal process
against any such asset;

 

		(d)	any person (entitled to do so) appoints an administrator, receiver or liquidator to any Chargor or files
such a notice with the court; or

 

		(e)	if any other floating charge created by that Chargor crystallises for any reason.

 

		4.3	Crystallisation: Reconversion

 

Any
charge which has crystallised under Clauses 4.1 or 4.2 may, by notice in writing given at any time by the Lender to the Chargor, be reconverted
into a floating charge (on the terms of Clause ‎3.1) in relation to
the Charged Assets specified in such notice. 

 

    5

     

    

 

		5.	FURTHER ASSURANCE

 

Except as would otherwise be inconsistent
with this Deed, the Chargor undertakes promptly upon request by the Lender to execute (in such form as the Lender may require) such documents
(including assignments, conveyances, assurances of the Charged Assets, transfers, mortgages, charges, notices, orders, directions and
instructions) in favour of the Lender or its nominees or any Receiver and to do all such assurances and things as the Lender may reasonably
require from time to time for:

 

		5.1	perfecting and/or protecting (by registration or in any other way) the
Security created or intended to be created by this Deed or the priority of such Security;

 

		5.2	conferring upon the Lender such Security as it may require over the
assets of the Chargor outside of Hong Kong which if in Hong Kong would form part of or be intended to form part of the Charged Assets;

 

		5.3	facilitating the realisation of all or any part of the Charged Assets;
and

 

		5.4	for exercising all powers, authorities and discretions conferred on
the Lender or any Receiver pursuant to this Deed or by law.

 

		6.	GENERAL UNDERTAKINGS WITH RESPECT TO the Charged Assets

 

The Chargor undertakes to the Lender
with respect to the Charged Assets that:

 

		6.1	Negative Pledge

 

save as any lien arising by operation
of law or any Security not prohibited or permitted by the Loan Documents, it shall not, without the prior consent in writing of the Lender,
create or attempt to create or permit to subsist or arise any Security on, over or affecting the Charged Assets or any part of them other
than any Security created under this Deed;

 

		6.2	Disposals

 

save to the extent not prohibited
or permitted by the Loan Documents, it shall not dispose of the Charged Assets or any part of them or agree to do so and for these purposes
the term “dispose” shall include any form of disposal of any interest in any asset including any transfer, declaration of trust,
assignment, sale or the creation of any other form of legal or equitable interest in or over any asset or any option in respect of any
of the foregoing;

 

		6.3	Liability of Lender

 

Neither the Lender
nor any of its nominees will have any liability for any loss arising out of or in connection with the exercise or non-exercise of any
rights or powers attaching or accruing to the Charged Assets or which may be exercised by the Lender or any nominee for the Lender under
this Deed.

 

    6

     

    

 

		7.	UNDERTAKINGS WITH RESPECT TO the Charged Assets

 

The Chargor undertakes to the Lender
with respect to Charged Assets that:

 

		7.1	Realising Receivables

 

the Chargor shall,
following an Event of Default if called on to do so by the Lender, execute a legal assignment of the Receivables to the Lender on such
terms as the Lender may require and give notice of that assignment to the debtors from whom the Receivables are due, owing or incurred.

 

		7.2	Filings and registrations

 

		(a)	The Chargor must:

 

		(i)	immediately after execution of this Deed, create and maintain a register of charges to the extent this
has not already been done;

 

		(ii)	enter particulars of the security interests created pursuant to this Deed in the register of charges and
immediately after entry of such particulars has been made, and in any event within 3 Business Days after execution of this Deed, provide
the Lender with a certified true copy of the updated register of charges;

 

		(iii)	effect registration, or assist the Lender in effecting registration of this Deed with the Hong Kong Companies
Registry within two days after execution of this Deed pursuant to the Companies Ordinance; and

 

		(iv)	immediately on receipt, deliver or procure to be delivered to the Lender, the certificate of registration
of charge issued by the Hong Kong Companies Registry evidencing that the requirements of the Companies Ordinance as to registration have
been complied with.

 

		(b)	The Chargor shall make all such other filings and registrations required or desirable under law as the
Lender may specify in order to perfect, protect, maintain or improve any Security created or intended to be created by this Deed. 

 

		8.	RIGHTS OF THE Lender

 

		8.1	Enforcement

 

At any time on or after the occurrence
of an Event of Default, the Security created pursuant to this Deed shall be immediately enforceable and save as may be provided in this
Deed, the powers conferred to the Lender in this Deed shall be immediately exercisable following the occurrence of an Event of Default:

 

		(a)	enforce all or any part of the Security created by this Deed and take possession of or dispose of all
or any of the Charged Assets in each case at such times and upon such terms as it sees fit;

 

		(b)	appoint under seal or in writing under its hand any one or more persons to be a Receiver under this Deed
of the whole or any part of the Charged Assets; and

 

		(c)	whether or not it has appointed a Receiver, exercise all of the powers, authorities and discretions granted
to a Receiver by this Deed or by law.

 

    7

     

    

 

		8.2	No Restrictions on Consolidation

 

The Lender shall have the right to
consolidate all or any of the Security created by or pursuant to this Deed with any other Security in existence at any time. Such power
may be exercised by the Lender at any time on or after the occurrence of an Event of Default.

 

		8.3	Restrictions on Exercise of Power of Sale

 

Paragraph 11 of the Fourth Schedule
to the CPO shall not apply to this Deed and the power of sale arising under the CPO shall apply to the Lender and shall arise on the date
of occurrence of an Event of Default (and the Secured Obligations shall be deemed to have become due and payable for that purpose). The
power of sale and other powers conferred by sections 51 (Powers of mortgagee and receiver) and 53 (Sale by mortgagee) of
and the Fourth Schedule (Powers of mortgagee and receiver) to the CPO as varied or extended by this Deed and those powers conferred
(expressly or by reference) on a Receiver shall be immediately exercisable by the Lender at any time on or after the occurrence of an
Event of Default.

 

		8.4	No Prior Notice Needed

 

The powers of the Lender set out in
Clauses 8.2 (No Restrictions on Consolidation) and 8.3 (Restrictions on Exercise of Power of Sale) above may be exercised
by the Lender without prior notice to the Chargor.

 

		8.5	Construction of Enforcement Powers

 

The powers of the Lender under this
Deed shall have as wide and flexible a range of powers as may be conferred by any applicable law. Except to the extent provided by law,
none of the powers described in this Clause 8 (Right of the Lender) will be affected by the winding-up or dissolution of the
Chargor.

 

		8.6	Delegation

 

The Lender may delegate in any manner
to any person any rights exercisable by the Lender under this Deed. Any such delegation may be made upon such terms and conditions (including
power to sub-delegate) as the Lender thinks fit.

 

		8.7	Exercise of Rights not Foreclosure

 

If the Lender exercises any of the
rights conferred on it by paragraph 3 of Schedule 1 (Receiver’s Powers), the same shall not be treated as an absolute appropriation
of or foreclosure on the Charged Assets to the exclusion of the Chargor and in extinguishment of its interests therein, unless the Lender
shall otherwise notify the Chargor (whether before or after the relevant appropriation or foreclosure has been effected), in which latter
event any such appropriation or foreclosure shall be treated as a sale of the Charged Assets at a fair market value and the Secured Obligations
shall be reduced by an equivalent amount.

 

		8.8	Lender May Purchase Charged Assets

 

In any disposal pursuant to paragraph
3 of Schedule 1 (Receiver’s Powers), the Lender may, subject to compliance with applicable law, and any rules or regulations laid
down by any governmental or other agency or authority, purchase the whole or any part of the Charged Assets or rights for full market
value disposed of free from any rights of redemption on the part of the Chargor which are hereby waived and released.

 

    8

     

    

 

		8.9	Conversion of currency

 

		(a)	For the purpose of, or pending the discharge of, any of the Secured Obligations, the Lender may convert
any monies received, recovered or realised by it under this deed (including the proceeds of any previous conversion under this Clause
8.9) from their existing currencies of denomination into any other currencies of denomination that the Lender may think fit.

 

		(b)	Any such conversion shall be effected at the Lender’s then prevailing spot selling rate of exchange
for such other currency against the existing currency.

 

		(c)	Each reference in this Clause 8.9 to a currency extends to funds of that currency and, for the avoidance
of doubt, funds of one currency may be converted into different funds of the same currency.

 

		9.	EXONERATION

 

		9.1	Exoneration

 

The Lender shall not, nor shall any
Receiver, by reason of its or the Receiver entering into possession of the Charged Assets or any part thereof, be liable to account as
mortgagee in possession or be liable for any loss or realisation or for any default or omission for which a mortgagee in possession might
be liable; but every Receiver duly appointed by the Lender under this Deed shall for all purposes be deemed to be in the same position
as a receiver duly appointed by a mortgagee under the CPO save to the extent that the provisions of the CPO are varied by or are inconsistent
with the provisions of this Deed when the provisions hereof shall prevail and every such Receiver and the Lender shall in any event be
entitled to all the rights, powers, privileges and immunities conferred by the CPO on mortgagees and receivers duly appointed under the
CPO.

 

		9.2	Indemnity

 

The Lender and every Receiver, attorney,
delegatee, director, officer, manager, agent, employee or other person appointed by the Lender hereunder shall be entitled to be indemnified
by the Chargor and/or out of the Charged Assets or any part thereof in respect of all liabilities and expenses incurred by it or him in
the execution of any of the powers, authorities or discretions vested in it or him pursuant to this Deed and against all actions, proceedings,
judgments, losses, expenses, taxes, charges, costs, claims and demands in respect of any matter or thing done or omitted in any way relating
to the Charged Assets or any part of them. The Lender and any such Receiver may retain and pay all sums in respect of which it is indemnified
out of any monies received under the powers conferred by this Deed. The Lender is not obliged to take any action hereunder unless it has
been identified and/or secured to its satisfaction any liabilities it may incur by doing so.

 

    9

     

    

 

		10.	APPOINTMENT OF RECEIVER

 

		10.1	Appointment

 

At any time on or after the occurrence
of an Event of Default, or at the request of the Chargor, the Lender may, without prior notice to the Chargor, in writing (under seal,
by deed or otherwise under hand) appoint a Receiver in respect of the Charged Assets or any part thereof and may in like manner from time
to time (and insofar as it is lawfully able to do) remove any Receiver and appoint another in his stead.

 

		10.2	More than one Receiver

 

Where more than one Receiver is appointed,
each joint Receiver shall have the power to act severally, independently of any other joint Receiver, except to the extent that the Lender
may specify to the contrary in the appointment.

 

		10.3	Receiver as agent

 

A Receiver shall be the agent of the
Chargor which shall be solely responsible for his acts or defaults and for his remuneration. No Receiver shall at any time act as agent
of the Lender.

 

		10.4	Receiver’s Remuneration

 

A Receiver shall be entitled to remuneration
for his services at a rate to be determined by the Lender from time to time (and without being limited to any maximum rate specified by
any statute or statutory instrument).

 

		11.	RECEIVER’S POWERS

 

		11.1	Powers

 

A Receiver shall have (and be entitled
to exercise) in relation to the Charged Assets over which he is appointed the following powers (as the same may be varied or extended
by the provisions of this Deed):

 

		(a)	all of the powers and rights conferred from time to time on receivers, mortgagors and mortgagees in possession
by the CPO;

 

		(b)	all the powers and rights of a legal and beneficial owner and the power to do or omit to do anything which
the Chargor itself could do or omit to do; and

 

		(c)	all the powers and rights outlined in Schedule 1 (Receiver’s Powers).

 

		11.2	Powers may be Restricted

 

The powers granted to a Receiver pursuant
to this Deed may be restricted by the instrument (signed by the Lender) appointing him but they shall not be restricted by any winding-up
or dissolution of the Chargor.

 

    10

     

    

 

		12.	PROTECTION OF PURCHASER

 

		12.1	Absence of Enquiry

 

No person or persons dealing with
the Lender or any Receiver appointed by it shall be concerned to enquire whether any event has happened upon which any of the powers in
this Deed are or may be exercisable or otherwise as to the propriety or regularity of any exercise of such powers or of any act purporting
or intended to be an exercise of such powers or whether any amount remains secured by this Deed. All the protections to purchasers and
persons dealing with receivers contained in sections 52, 53 and 55 of the CPO shall apply to any person purchasing from or dealing with
the Lender or any such Receiver.

 

		12.2	Receipt: Conclusive Discharge

 

The receipt of the Lender or any Receiver
shall be a conclusive discharge to any purchaser of the Charged Assets.

 

		13.	POWER OF ATTORNEY AND DELEGATION

 

		13.1	Power of Attorney: General

 

The Chargor irrevocably and by way
of security (within the meaning of section 4 of the Powers of Attorney Ordinance (Cap. 31 of the Laws of Hong Kong)) appoints the Lender
and any Receiver severally to be its attorney in its name and on its behalf and as its act and deed:

 

		(a)	to date, execute and/or deliver any documents or instruments which the Lender or such Receiver may require
for perfecting the title of the Lender to the Charged Assets or for vesting the same in the Lender, its nominee or any purchaser;

 

		(b)	to sign, execute, seal and deliver and otherwise perfect any further security document which the Chargor
is required to enter into pursuant to this Deed; and

 

		(c)	otherwise generally to sign, seal, execute and deliver all deeds, assurances, agreements and documents
and to do all acts and things which may be required for the full exercise of all or any of the powers conferred on the Lender or any Receiver
under this Deed or which the Chargor is required to do pursuant to this Deed or which may be deemed expedient by the Lender or a Receiver
in connection with any preservation, disposition, realisation or getting in by the Lender or such Receiver of the Charged Assets or any
part thereof or in connection with any other exercise of any other power under this Deed.

 

		13.2	Power of Attorney: Ratification

 

The Chargor ratifies and confirms
and agrees to ratify and confirm all acts and things which any attorney mentioned in this Clause 13 shall do or purport to do in exercise
of the powers granted by this Clause 13.

 

    11

     

    

 

		13.3	Power of Attorney: General Delegation

 

The Lender and any Receiver shall
have full power to delegate the powers, authorities and discretions conferred on it or him by this Deed (including the power of attorney)
on such terms and conditions as it or he shall see fit which shall not preclude exercise of those powers, authorities or discretions by
it or him or any revocation of the delegation or any subsequent delegation. Neither the Lender nor any Receiver will be in any way liable
to the Chargor for any loss or liability arising from any act, default, omission or misconduct on the part of any delegate selected by
it in good faith.

 

		14.	Application Of Monies Received Under This Deed

 

Any monies received as a result of
the exercise of the rights and powers under this Deed shall, subject to the repayment of any claims having priority to this Deed, be applied
for the following purposes and in the following order of priority:

 

		14.1	in satisfaction of all costs (including but not limited to all legal
fees), charges and expenses and payments (including payments made in accordance with paragraphs (a), (b) and (c) of section 54 of the
CPO) made or incurred by the Lender or the Receiver and of remuneration to the Receiver under or in connection with this Deed in such
order as the Lender shall in its absolute discretion decide;

 

		14.2	in or towards payment pari passu and rateably of: 

 

		(a)	all accrued interest remaining unpaid in respect of the Loan; and

 

		(b)	all principal moneys due or in respect of the Loan; and

 

		14.3	in towards payment pro rata of any other sum due but unpaid under the
Loan Documents; and

 

		14.4	at the end of the Security Period, in payment of the balance (if any)
to a bank account to be notified in writing to the Lender by the Chargor (without prejudice to, or liability in respect of, any question
as to how such payment into such account shall be dealt with as between the Borrowers and any other person).

 

		15.	RELEASE OF SECURITY

 

		15.1	Release

 

If:

 

		(a)	all the Secured Obligations have been irrevocably paid in full and the Lender has no actual or contingent
liability to advance further monies to, or incur liability on behalf of, the Chargor; or

 

		(b)	the Chargor is entitled pursuant to any provision of the Secured Credit Agreement to have the Charged
Assets released from the Security,

 

the Lender shall, at the request and
cost of each Chargor, execute any documents (or procure that its nominees execute any documents) or take any action which may be necessary
to release the Charged Property from the Security constituted by this Deed.

 

    12

     

    

 

		15.2	Avoidance of Payments

 

		(a)	No amount paid, repaid or credited to the Lender shall be deemed to have been irrevocably paid if the
Lender considers that the payment or credit of such amount is capable of being avoided or reduced by virtue of any laws applicable on
bankruptcy, insolvency, liquidation or similar laws.

 

		(b)	If any amount paid, repaid or credited to the Lender is avoided or reduced by virtue of any laws applicable
on bankruptcy, insolvency, liquidation or any similar laws then any release, discharge or settlement between the Lender and the Chargor
shall be deemed not to have occurred and the Lender shall be entitled to enforce this Deed subsequently as if such release, discharge
or settlement had not occurred and any such payment had not been made.

 

		16.	AMOUNTS PAYABLE

 

		16.1	No Deduction

 

All payments under this Deed by the
Chargor shall be made without any set-off, counterclaim or equity and (subject to the following sentence) free from, clear of and without
deduction for any taxes whatsoever, present or future. If the Chargor is compelled by the law or regulation of any applicable jurisdiction
(or by an order of any regulatory authority in such jurisdiction) to withhold or deduct any sums in respect of taxes from any amount payable
to the Lender under this Deed or, if any such withholding or deduction is made in respect of any recovery under this Deed, the Chargor
shall pay such additional amount so as to ensure that the net amount received by the Lender shall equal the full amount due to it under
the provisions of this Deed (had no such withholding or deduction been made).

 

		16.2	Currency of Payment

 

The obligation of the Chargor under
this Deed to make payments in any currency shall not be discharged or satisfied by any tender, or recovery pursuant to any judgment or
otherwise, expressed in or converted into any other currency, except to the extent to which such tender or recovery results in the effective
receipt by the Lender of the full amount of the currency expressed to be payable under this Deed.

 

		16.3	Currency Indemnity

 

		(a)	If any sum due from the Chargor under this Deed (a “Sum”), or any order, judgment or
award given or made in relation to a Sum, has to be converted from the currency (the “First Currency”) in which that
Sum is payable into another currency (the “Second Currency”) for the purpose of:

 

		(i)	making or filing a claim or proof against the Chargor;

 

		(ii)	obtaining or enforcing an order, judgment or award in relation to any litigation or arbitration proceedings;
or

 

		(iii)	applying the Sum in satisfaction of any of the Secured Obligations,

 

the Chargor shall, as an independent
obligation, within ten (10) Business Days of demand, indemnify the Lender against any cost, loss or liability arising out of or as a result
of the conversion including any discrepancy between (1) the rate of exchange used to convert that Sum from the First Currency into the
Second Currency and (2) the rate or rates of exchange available to the Lender at the time of its receipt of that Sum.

 

    13

     

    

 

		(b)	The Chargor waives any right it may have in any jurisdiction to pay any amount under this Deed in a currency
unit other than that in which it is payable.

 

		17.	MISCELLANEOUS

 

		17.1	The Chargor

 

This Deed shall be binding on the
successors and permitted assigns of the Chargor.

 

		17.2	Assignment and Transfer

 

The Chargor may not assign any rights
it has under this Deed without the prior written consent of the Lender. The Lender may assign and transfer all or any part of its rights
and obligations under this Deed in accordance with the provisions of the Secured Credit Agreement.

 

		17.3	Disclosure

 

The Lender may disclose any information
about the Chargor, the Secured Credit Agreement or this Deed as the Lender shall consider appropriate in accordance with the Secured Credit
Agreement.

 

		17.4	Remedies and Waivers Cumulative

 

Save as expressly provided in this
Deed, no failure to exercise, or delay in exercising, on the part of any party hereto any right, power or privilege under this Deed shall
operate as a waiver, nor shall any single or partial exercise of any right, power or privilege preclude any other or further exercise,
or the exercise of any other right, power or privilege. No waiver by the Lender shall be effective unless it is in writing. The rights
and remedies of the Lender are cumulative and not exclusive of any rights or remedies provided by law.

 

		17.5	Set-Off, Combination of Accounts and Lien

 

The Lender may (but shall not be obliged
to) set-off any obligation in respect of Secured Obligations which is due and payable by the Chargor against any obligation (contingent
or otherwise) owed by the Lender to the Chargor in payment of the Secured Obligations. The Lender may, at the cost of the Chargor, effect
any currency exchanges as it considers are appropriate to implement such set-off.

 

		17.6	Partial Invalidity

 

If, at any time, any provision of
this Deed is or becomes illegal, invalid or unenforceable in any respect under the law of any relevant jurisdiction, neither the legality,
validity or enforceability of the remaining provisions of this Deed, nor the legality, validity or enforceability of that provision under
the law of any other jurisdiction, shall in any way be affected or impaired.

 

    14

     

    

 

		17.7	Property

 

This Deed is and will remain the property
of the Lender.

 

		17.8	Continuing Security

 

This Deed shall
be a continuing security and shall not be discharged by any intermediate payment or satisfaction of the whole or any part of the Secured
Obligations.

 

		17.9	Additional Security

 

This Deed shall be in addition to
and not be affected by any other Security or guarantee at any time held by the Lender for all or any part of the Secured Obligations nor
shall any such other Security or guarantee of liability to the Lender of or by any person not a party to this Deed be in any way impaired
or discharged by this Deed nor shall this Deed in any way impair or discharge such other Security or guarantee.

 

		17.10	Variation of Security

 

This Deed shall not in any way be
affected or prejudiced by the Lender at any time dealing with, exchanging, releasing, varying or abstaining from perfecting or enforcing
any Security or guarantee referred to in Clause 17.9 (Additional Security) above or any rights which the Lender may at any time
have or giving time for payment or granting any indulgence or compounding with any person whatsoever.

 

		17.11	Enforcement of Other Security

 

The Lender shall not be obliged to
enforce any other Security it may hold for the Secured Obligations before enforcing any of its rights under this Deed.

 

		17.12	Redemption of Prior Incumbrances

 

The Lender may redeem or take a transfer
of any prior Security over the Charged Assets and may agree the accounts of prior incumbrancers. An agreed account shall be conclusive
and binding on the Chargor. Any amount paid in connection with such redemption or transfer (including expenses) shall be paid on demand
by the Chargor to the Lender and until such payment shall form part of the Secured Obligations.

 

		17.13	Stamp Duties

 

The Chargor covenants to pay to the
Lender or any Receiver, attorney, manager, agent or other person appointed by the Lender under this Deed immediately upon demand a sum
equal to any liability which the Lender, that Receiver, attorney, manager, agent or other person incurs in respect of stamp duty, registration
fee and other taxes which is or becomes payable in connection with the entry into, performance or enforcement of this Deed (including
any interest, penalties, liabilities, costs and expenses resulting from any failure to pay or delay in paying any such duty, fee or tax).

 

    15

     

    

 

		17.14	Costs and Expenses

 

The Chargor shall immediately upon
demand reimburse the Lender and any Receiver, attorney, manager, agent or other person appointed by the Lender under this Deed for all
costs and expenses (including all legal fees) incurred by the Lender, that Receiver, attorney, manager, agent or other person (on a full
indemnity basis together with any applicable tax) in connection with the negotiation, preparation and execution of this Deed, the completion
of the transactions and perfection of the Security contemplated by this Deed and the exercise, preservation and/or enforcement or attempted
enforcement of the Security created by or contemplated by this Deed.

 

		18.	calculations and certificates

 

		18.1	Accounts

 

In any litigation or arbitration proceedings
arising out of or in connection with this Deed, the entries made in the records maintained by the Security Agent in connection with this
Deed are, in the absence of manifest error, conclusive evidence of the matters to which they relate.

 

		18.2	Certificates and Determinations

 

Any certification or determination
by the Security Agent of a rate or amount under this Deed is, in the absence of manifest error, conclusive evidence of the matters to
which it relates.

 

		19.	NOTICES

 

Any
communication to be made under or in connection with this Deed shall be made in accordance with the provisions of Section 8.01 (a) (Notices
Generally) of the Secured Credit Agreement.

 

		20.	counterparts

 

This Deed may be executed in any number
of counterparts, and this has the same effect as if the signatures on the counterparts were on a single copy of this Deed.

 

		21.	ENTIRE AGREEMENT

 

This Deed, together with any agreements
or documents referred to herein, sets out the entire agreement and understanding between the Parties with respect to the subject matter
contained herein and supersedes all prior agreements, understandings, negotiations and discussions (whether oral or written) and all previous
agreements in relation to the subject matter contained herein are hereby terminated and shall have no further force or effect.

 

    16

     

    

 

		22.	governing LAW

 

This Deed and any dispute or claim
arising out of or in connection with it or its subject matter, existence, negotiation, validity, termination or enforceability shall be
governed by and construed in accordance with Hong Kong law.

 

		23.	Waiver of immunities

 

Each Party irrevocably waives, to
the extent permitted by applicable law, with respect to itself and its revenues and assets (irrespective of their use or intended use),
all immunity on the grounds of sovereignty or other similar grounds from:

 

		(a)	suit;

 

		(b)	jurisdiction of any court;

 

		(c)	relief by way of injunction or order for specific performance or recovery of property;

 

		(d)	attachment of its assets (whether before or after judgment); and

 

		(e)	execution or enforcement of any judgment or award to which it or its revenues or assets might otherwise
be entitled in any proceedings in the courts of any jurisdiction (and irrevocably agrees, to the extent permitted by applicable law, that
it will not claim any immunity in any such proceedings).

 

		24.	dispute resolution

 

		24.1	Except for Lender’s non-judicial foreclosure of any security interests
in real or personal property, exercise of self-help remedies (including, without limitation, set-off), appointment of a receiver and temporary,
provisional or ancillary remedies (including, without limitation, writs of attachment, writs of possession, temporary restraining orders
or preliminary injunctions) (collectively, the “Secured Creditor Remedies”), any
dispute arising out of or in connection with this Deed or the other Loan Documents, including any question regarding its existence, validity
or termination, shall be referred to and finally resolved by arbitration under the Rules of London Court of International Arbitration,
which are deemed to be incorporated by reference into this clause.

 

		24.2	The number of arbitrators shall be three (3). Each party or “side”
in the dispute shall nominate one (1) arbitrator, and the two party-nominated arbitrators shall nominate a third arbitrator, who shall
serve as presiding arbitrator. Parties who are Affiliates shall be considered one side. In the event the parties cannot agree on the composition
of two separate “sides” for the purposes of constituting the arbitral tribunal, and the then the London Court of International
Arbitration shall determine the composition of the sides, and the arbitral tribunal shall be nominated as set forth above.

 

		24.3	The seat, or legal place, of arbitration shall be New York, New York,
United States of America.

 

		24.4	The language to be used in the arbitral proceedings shall be English.
The arbitration proceedings shall be confidential.

 

    17

     

    

 

		24.5	Each party must bear its own costs in connection with any dispute, provided
however that: (i) all interim expenses or fees payable to arbitrators or institutions conducting an arbitration must be shared equally
by the parties interested in the dispute (and to the extent parties to the dispute are Affiliates, they shall be deemed to be one party
for the purposes of allocation of such interim expenses); and (ii) the arbitral tribunal may apportion arbitration costs, including legal
fees, as part of the arbitral award. 

 

		24.6	Notwithstanding any provision of this Clause 24 (Dispute Resolution),
nothing in this Clause 24 (Dispute Resolution) prevents any party from applying to a court of competent jurisdiction: (i) for injunctive
relief, a preservation order or other interim relief; (ii) to seek recognition and enforcement of any arbitral award or determination
made under this Deed; or (iii) to aid in Lender’s enforcement of any Secured Creditor Remedies.

 

		24.7	Notwithstanding any of the foregoing provisions of this Clause 24 (Dispute
Resolution), the arbitral tribunal shall have the power to order consolidation of any other dispute, controversy, difference or claim
arising between the parties in relation to or connected with this Deed and which is already the subject of existing arbitration proceedings,
unless the parties otherwise agree in writing. 

 

		24.8	Notwithstanding the existence of any dispute or the conduct of any arbitration
proceedings pursuant to this Deed, this Deed shall remain in full force and effect and the parties must continue to perform their obligations
hereunder.

 

		25.	contracts (rights of third parties) ordinance

 

Nothing in this Deed is intended to
grant to any third party and right to enforce any term of this Deed or to confer on any third party any benefits under this Deed for the
purposes of the Contracts (Rights of Third Parties) Ordinance (Chapter 623 of the Laws of Hong Kong), the application of which legislation
is hereby expressly excluded.

 

		26.	Punctual Performance

 

Time is of the essence of this Deed,
but no failure or delay by the Lender in exercising or enforcing any right, power or privilege hereunder shall operate as a waiver thereof,
nor shall any single or partial exercise or enforcement of any right, power or privilege preclude any further exercise or enforcement
thereof or the exercise or enforcement of any other right, remedy, power or privilege. The rights, remedies, powers and privileges herein
provided are cumulative and not exclusive of any rights and remedies powers or privileges provided by law.

 

IN WITNESS whereof this Deed has been duly
executed in Hong Kong and delivered as a deed on the date first above written.

 

    18

     

    

 

Schedule
1

Receiver’s Powers

 

The Receiver shall have the right, either in his
own name or in the name of the Chargor or otherwise and in such manner and upon such terms and conditions as he thinks fit, and either
alone or jointly with any other person:

 

		1.	to take immediate possession of, get in and collect the Charged Assets;

 

		2.	to borrow or raise money either unsecured or on the Security of the Charged Assets (either in priority
to the Security created by this Deed or otherwise);

 

		3.	to sell, transfer, assign, exchange or otherwise dispose of or realise the Charged Assets to any person
either by public or private offer or auction, tender or private contract and for a consideration of any kind (which may be payable or
delivered in one amount or by instalments spread over a period or deferred);

 

		4.	manage and use the Charged Assets and to exercise and do (or permit the Chargor or any nominee of it to
exercise and do) all such rights and things as he thinks fit and as if he were the absolute beneficial owner of the Charged Assets;

 

		5.	to appoint and discharge managers, officers, agents, accountants, servants, workmen and others for the
purposes of this Deed upon such terms as to remuneration or otherwise as he thinks fit;

 

		6.	to exercise any conversion rights or voting rights in respect of the Charged Assets;

 

		7.	to settle, adjust, refer to arbitration, compromise and arrange any claims, accounts, disputes, questions
and demands with or by any person who is or claims to be a creditor of the Chargor relating to the Charged Assets;

 

		8.	to bring, prosecute, enforce, defend and abandon actions, suits and proceedings in relation to the Charged
Assets;

 

		9.	to redeem any Security (whether or not having priority to the Security created by this Deed) over the
Charged Assets and to settle the accounts of any person with an interest in the Charged Assets;

 

		10.	to execute any documents in the name of the Chargor (whether under hand, or by way of deed or by utilisation
of the company seal of the Chargor);

 

		11.	to purchase, lease, hire or otherwise acquire any asset or right of any description that he, in his absolution
discretion, considers necessary or desirable for the improvement or realisation of the whole or any party of the Charged Assets or otherwise
for the benefit of the whole or any part of the Charged Assets;

 

		12.	to form any subsidiary of the Chargor and transfer to that subsidiary any Charged Asset;

 

		13.	to appoint any professional adviser in relation to discharge of its duties as a receiver as it sees fit;
and

 

		14.	to do all things which, in the opinion of the Receiver, are incidental to any of the powers, functions,
authorities or discretions conferred or vested in the Receiver pursuant to this Deed or upon receivers by statute or law generally.

 

    19

     

    

 

	

The Chargor	 	 
	 	 	 
	Executed and Delivered as a deed by 

AiPharma Asia Limited	
    )

    )

    )

    )
	 
	acting by Alessandro Gadotti as attorney for and on 	)	
	behalf of AiPharma Asia Limited under a power of 	)	
	attorney dated 28 August 2021 	)	.................................................
	 	)	AiPharma
Asia Limited by his attorney

	 	 	 
	 	
    
	/s/ Alessandro Gadotti

 

    20

     

    

 

	The Lender	 	 
	 	 	 
	SIGNED for and on behalf of	)	 
	ADITXT, INC.	)	 
	 	)	 
	 	)	/s/ Amro Albanna
	 	)	Amro Albanna]
	 	)	 

 

 

21Exhibit 10.10

 

Execution Copy

 

TRANSACTION
AGREEMENT

 

This TRANSACTION AGREEMENT
(this “Agreement”), dated as of October 4, 2021, by and between AiPharma Global Holdings LLC, a Delaware limited liability
company (“AiPharma”), and Aditxt, Inc., a Delaware corporation (“Aditxt”, and together with AiPharma,
the “Parties” and each, a “Party”) and replaces in its entirety and terminates that certain letter
agreement between the Parties dated August 24, 2021.

 

R E
C I T A L S

 

WHEREAS, the Parties desire
to enter into a series of transactions, including the transactions set forth in Exhibit A (Material Terms for Subsequent Transaction)
hereto, pursuant to which (i) Aditxt would acquire Holdco (as defined in Exhibit A) which will hold the Acquired Assets (as
hereinafter defined), and (ii) AiPharma would be issued shares of Aditxt Common Stock (as defined below), as further provided herein.
An organization chart of AiPharma and its subsidiaries as of the date hereof is attached hereto as Schedule 6.

 

NOW, THEREFORE, in consideration
for the promises contained herein and the mutual obligations of the Parties, the receipt and sufficiency of which are hereby expressly
acknowledged, the Parties, intending to be legally bound, hereby agree as follows:

 

1.
Initial Transaction.

 

(a)
Upon the execution and delivery of this Agreement, AiPharma will be permitted to borrow under the Loan Documents (as defined below)
an additional principal amount of $8,500,000 (the “Borrowing Capacity”) as follows: during the period beginning on
the date hereof and ending upon the earlier of (i) the Initial Closing (as defined in Exhibit A) and (ii) the termination
of this Agreement in accordance with its terms (such period, the “Interim Period”), Aditxt shall promptly lend (unless
AiPharma elects to not borrow) 70% of any and all net cash proceeds Aditxt receives in connection with (A) exercises of the Existing Aditxt
Warrants (as defined below) or (B) any other capital raises, in each case, to AiPharma under the Loan Documents (“Additional
Borrowings”) until the aggregate amount of the Additional Borrowings actually provided to AiPharma is equal to the Borrowing
Capacity. To the extent the exercise of the Existing Aditxt Warrants is unlikely to fund sufficient Additional Borrowings to reach the
Borrowing Capacity, Aditxt shall use commercially reasonable efforts to fund Additional Borrowings by raising additional funds through
other available means; provided, that Aditxt shall consult with (and consider in good faith any comment from) AiPharma in connection
therewith. Any and all Additional Borrowings shall bear interest on the terms set forth under the Loan Documents; provided, that
any payment of such interest shall be deferred (and shall not become due and payable) during the Interim Period.

 

(b)
Following the date hereof, each of the Parties shall use its commercially reasonable efforts, acting in good faith, to amend the
Loan Documents as promptly as practicable in a manner consistent with and reflecting this Agreement (including Section 1(a) and
Section 11) and the transactions contemplated hereby, and until such amendment is executed, the “Maturity Date”
(as defined thereunder) shall be extended to November 30, 2021 (including with respect to all principal, interest and any other payments
due under the Loan Documents). The Parties agree that, under the Loan Documents, the term “Combination LOI” shall mean this
Agreement, and that “Definitive Agreement” shall mean the Definitive Purchase Agreement contemplated by Exhibit A (and
not this Agreement).

 

     

    

    

 

(c)
“Loan Documents” means, collectively, each of the following documents that were entered into between the Parties
on August 27, 2021, pursuant to which Aditxt made a secured loan to AiPharma in the principal amount
of $6.5 million: (i) the Secured Credit Agreement, dated as of August 27, 2021, by and among AiPharma, AiPharma Holdings Limited,
AiPharma Asia Limited, and Aditxt, (ii) the Security Agreement, dated as of August 27, 2021, by and between AiPharma Asia Limited and
Aditxt, (iii) the Security Agreement by HK Opco governed by Delaware law, the Security Agreement by BVI Opco governed by Delaware law
(including the “Shareholder Direction” attached thereto), the Floating Charge of HK Opco governed by the laws of Hong Kong,
the Security Agreement by BVI Opco governed by the laws of the British Virgin Islands, and certain documents, instruments, agreements
and financing statements relating thereto, (iv) the Direction Regarding Payment of Dividends by and between AiPharma Limited and Aditxt,
(v) the Floating Charge, dated as of August 27, 2021, by and between AiPharma Asia Limited and Aditxt, (vi) Statement of Particulars of
Charge, dated as of August 27, 2021, by and between AiPharma Asia Limited and Aditxt, and (vii) the Security Agreement, dated as of August
27, 2021, by and between AiPharma Limited and Aditxt.

 

2.
Subsequent Transaction. Unless this Agreement is terminated under Section 11, the Parties hereby agree to enter into
a definitive purchase agreement (the “Definitive Purchase Agreement”) for a subsequent transaction (the “Subsequent
Transaction”) including the terms set forth on Exhibit A (the “Material Terms”) as promptly as practicable
after the date hereof but in any event no later than the Outside Date. In furtherance of the foregoing, the Parties agree to act in good
faith and use all reasonable efforts in all respects to (i) negotiate and agree on the Definitive Purchase Agreement and other definitive
agreements for the Subsequent Transaction reflecting the Material Terms (collectively, the “Definitive Documents”),
and (ii) execute and deliver the Definitive Documents, in each case, as promptly as practicable after the date hereof but in any
event no later than the Outside Date. For the avoidance of doubt, the obligations of the Parties stated herein are legally binding in
all respects as further provided herein, and the Parties have agreed to the Material Terms and are obligated to reflect them in the Definitive
Documents and perform and implement all actions required pursuant to the Material Terms.

 

3.
Representations and Warranties of each Party. Each Party represents and warrants (solely with respect to itself) to the
other Party as of the date hereof as follows (provided, that only Aditxt is making the representations set forth in Section 3(g)
and Section 3(h) and only AiPharma is making the representations set forth in Section 3(i)), except in each case as
is set forth in, as applicable, the Disclosure Letter of AiPharma, attached as Schedule 1 hereto, or the Disclosure Letter of Aditxt,
attached as Schedule 2 hereto (as applicable, the “Disclosure Letters”, each of which will be delivered by the
applicable Party to the other Party within seven (7) business days after the date hereof):

 

(a)
Existence. Such Party is a limited liability company or corporation, as applicable, duly formed or incorporated and validly
existing in good standing under the laws of the State of Delaware, with all requisite power and authority to own, use, lease and operate
its properties and conduct its business in the manner presently conducted, and is duly qualified to transact business in each jurisdiction
where it is so required.

 

    2

    

    

 

(b)
Authorization. The execution and delivery, and performance by such Party, of this Agreement has been authorized by all necessary
limited liability company or corporate action on the part of such Party and no further limited liability company or corporate action is
required by such Party, its officers, its board of directors, or its equityholders in connection with this Agreement or the transactions
contemplated hereby (other than as set forth in the Definitive Documents with respect to the Subsequent Transaction, which will be subject
to the approvals set forth in Exhibit A among others).

 

(c)
No Contravention. Except as disclosed in the applicable Disclosure Letter, the entry into this Agreement by such Party and
the undertaking of the transactions contemplated hereby will not cause such Party to breach or contravene: (i) its certificate of
incorporation, by-laws or limited liability company agreement, as applicable; (ii) any material agreement such Party has with any
other third party (and does not constitute an event of default under any such agreement); or (iii) any applicable law.

 

(d)
Binding Obligations. This Agreement has been duly executed and delivered by such Party and constitutes a legal, valid and
binding obligation of such Party, enforceable against such Party in accordance with its terms, subject to bankruptcy, insolvency, fraudulent
transfer, reorganization, moratorium and similar laws of general applicability, relating to or affecting creditors’ rights generally.

 

(e)
Consents. Except as disclosed in the applicable Disclosure Letters, there are no consents, approvals, authorizations, orders
or agreements of any governmental authorities or any other persons or entities which may be required for the execution, delivery and performance
by such Party of this Agreement (other than as set forth in the Definitive Documents with respect to the Subsequent Transaction, which
will be subject to the approvals set forth in Exhibit A among others).

 

(f)
Investment. Each Party hereby respectively makes the representations set forth on Exhibit B hereto.

 

(g)
Aditxt Capitalization. Except as set forth in the Aditxt Disclosure Letter, as of September 30, 2021: (i) the authorized
capital stock of Aditxt consists of (A) 100,000,000 shares of common stock, par value $0.001 per share, of Aditxt (“Aditxt
Common Stock”), and (B) 3,000,000 shares of preferred stock, par value $0.001 per share (the “Aditxt Preferred Stock”);
(ii) (A) 24,077,013 shares of Aditxt Common Stock are issued and outstanding, (B) zero (0) shares of Aditxt Preferred Stock
are issued and outstanding, (C) 10,276,217 warrants to purchase 10,276,217 shares of Aditxt Common Stock are outstanding (collectively,
the “Existing Aditxt Warrants”), (D) 39,000 shares of Common Stock to be issued to consultants (E) 3,000,000 securities
to be issued under the 2021 Omnibus Equity Incentive Plan, of which 1,575,400 have been approved by the Board of Directors of Aditxt (the
“Board) and/or compensation committee of the Board awarded as of the date of this Agreement and 2,478,000 securities, including
options, to be issued pursuant to awards granted under the Aditxt 2017 Equity Inventive Plan and (F) 67,466 other stock options to purchase
67,466 shares of Aditxt Common Stock outstanding. (collectively, the “Existing Aditxt Awards/Grants”); (iii) except
for the Existing Aditxt Warrants and the Existing Aditxt Awards/Grants, as disclosed above, , there are no options, warrants, convertible
securities or other rights, agreements, arrangements or commitments of any character relating to the issued or unissued capital stock
of Aditxt or obligating Aditxt to issue or sell any shares of capital stock of, or other equity interests in, Aditxt (except as may be
required in accordance with the terms of the Existing Aditxt Warrants); (iv) Aditxt is not a party to, or otherwise bound by, and
has not granted, any equity appreciation rights, participations, phantom equity or similar rights; (v) there are no voting trusts,
voting agreements, proxies, shareholder agreements or other agreements with respect to the voting or transfer of Aditxt Common Stock or
any of the equity interests or other securities of Aditxt; (vi) there are no outstanding contractual obligations of Aditxt to repurchase,
redeem or otherwise acquire any shares of Aditxt Common Stock; and (vii) there are no outstanding contractual obligations of Aditxt
to make any investment (in the form of a loan, capital contribution or otherwise) in, any person or entity.

 

    3

    

    

 

(h)
No Anti-Takeover Provisions.

 

(i)
None of Aditxt or any of its subsidiaries is party to a stockholder rights plan or agreement, “poison pill” or substantially
similar anti-takeover agreement or plan.

 

(ii) The board of directors of Aditxt has taken all necessary actions, including, without limitation, the approval of this
Agreement, the transactions contemplated hereby and the Subsequent Transaction, to ensure that the restrictions on business
combinations contained in Section 203 of the General Corporation Law of the State of Delaware do not apply to this Agreement, the
transactions contemplated hereby and the Subsequent Transaction.

 

(iii)
No other “control share acquisition”, “fair price”, “moratorium” or anti-takeover provision
of law, rule, regulation or requirement applies or purports to apply to this Agreement, the transactions contemplated hereby, or the Subsequent
Transaction.

 

(i) 
Holdco Capitalization. As of the Initial Closing, AiPharma will be the sole owner of 100% of the membership interests in
Holdco (as defined in Exhibit A). As of the Initial Closing, there will be no options, warrants, convertible securities or other rights,
agreements, arrangements or commitments of any character relating to the equity of Holdco or obligating Holdco or AiPharma to issue or
sell any shares of capital stock of, or other equity interests in, Holdco (other than this Agreement and the Definitive Documents). As
of the Initial Closing, Holdco will not be a party to, or otherwise bound by, or have granted, any equity appreciation rights, participations,
phantom equity or similar rights. As of the Initial Closing, there will be no voting trusts, voting agreements, proxies, shareholder agreements
or other agreements with respect to the voting or transfer of any of the equity interests or other securities of Holdco. As of the Initial
Closing, there will be no outstanding contractual obligations of Holdco to repurchase, redeem or otherwise acquire any Holdco equity.
As of the Initial Closing, there will be no outstanding contractual obligations of Holdco to make any investment (in the form of a loan,
capital contribution or otherwise) in, any person or entity.

 

    4

    

    

 

4.
Covenants of the Parties.

 

(a)
Public Announcements. The initial press release relating to this Agreement shall be a joint press release, the text of which
has been agreed to by the Parties. Thereafter, during the Interim Period, unless otherwise required by applicable laws, rules or regulations
or the requirements of the Nasdaq Stock Market, each Party shall obtain the prior written consent (not to be unreasonably withheld, conditioned
or delayed) of the other Party prior to issuing any press release or otherwise making any public statements with respect to this Agreement
or the Subsequent Transaction.

 

(b)
Alternative Transaction. The Parties mutually agree that during the Interim Period, each Party shall not, and shall cause
its affiliates, representatives and agents not to:

 

(i)
initiate, solicit, encourage, entertain, respond to, negotiate, accept or discuss, directly or indirectly, any proposal or offer
from any person or group of persons (other than the other Party), to acquire all or any significant part of the business and properties,
capital stock or capital stock equivalents of such Party (except as contemplated by Section 4(d) and any agreements entered into
prior to the date hereof) or any of such Party’s subsidiaries, whether by merger, purchase of stock, purchase of assets, tender
offer or otherwise (an “Alternative Transaction”);

 

(ii)
provide any nonpublic information to any third party in connection with an Alternative Transaction, or take any action intended
or designed to facilitate a possible Alternative Transaction; or

 

(iii)
approve recommend or enter into any Alternative Transaction.

 

provided, however, that, in the
event that Aditxt receives an unsolicited proposal, indication or communication related to any Alternative Transaction, Aditxt shall immediately
notify AiPharma and provide all terms and particulars relating to such proposal and allow AiPharma to make any alternative proposal (the
“Alternative Proposal”) to the Alternative Transaction within 5 business days of receipt of all the terms of the Alternative
Transaction and the Board, in the exercise of its fiduciary duties, will consider such Alternative Proposal before accepting any Alternative
Transaction. Should the board of directors of Aditxt, in the exercise of its fiduciary duties and upon the advice of its outside counsel
and any other advisor it deems appropriate, determine that such Alternative Transaction is superior to this Agreement and the transactions
contemplated hereby, including the Subsequent Transaction or the Alternative Proposal (if any), such that compliance with its fiduciary
duties requires, based on the advice of such outside counsel, the termination of this Agreement and the entry into the Alternative Transaction,
Aditxt shall have the right to enter into the Alternative Transaction subject to Aditxt terminating this Agreement pursuant to Section 11(a)(v)
and paying the fee required by Section 11(e).

 

(c)
Conduct of Business; Further Assurances. During the Interim Period, except as set forth in the applicable Disclosure Letters,
each Party:

 

(i)
shall conduct its respective business, in all material respects, in the ordinary course consistent with past practices;

 

(ii)
shall not, and shall cause its subsidiaries not to, issue any equity interests of such Party or such subsidiaries, other than,
with respect to Aditxt, as set forth in Section 4(d); and

 

(iii)
shall act in good faith, and shall not (and shall cause its subsidiaries not to) take actions that are inconsistent with or would
defeat the intent of this Agreement (including the Subsequent Transaction).

 

    5

    

    

 

(d)
Permitted Aditxt Issuances. Notwithstanding Section 4(c), during the Interim Period, Aditxt shall have the right
to: (i) issue shares of Aditxt Common Stock pursuant to exercises of Existing Aditxt Warrants; (ii) issue shares of Aditxt Common Stock
pursuant to exercises of Existing Aditxt Options; (iii) issue securities, in the ordinary course of business consistent with past practice,
pursuant to the Aditxt 2021 Omnibus Equity Incentive Plan and the Aditxt 2017 Equity Incentive Plan, as amended as of the date hereof;
(iv) issue securities to consultants in the ordinary course of business (outside of the foregoing plan(s)) up to 500,000 shares of Aditxt
Common Stock (with any issuances in excess thereof to be subject to consulting with AiPharma first); and (v) sell and issue Aditxt
securities pursuant to Aditxt’s currently effective S-3 shelf registration statement; provided, that with respect to any
sale or issuance of Aditxt securities pursuant to the foregoing clause (v), Aditxt shall consult with (and consider in good faith any
comment from) AiPharma in connection therewith.

 

(e)
Restructuring. Prior to the execution of the Definitive Agreement Purchase Agreement, AiPharma will cause all the assets
and liabilities of AiPharma (other than those mutually agreed with Aditxt to be excluded) to be directly or indirectly owned by Holdco
(as defined in Exhibit A) (the “Acquired Assets”), to the extent not already so owned by Holdco (the “Restructuring”).
Such assets and liabilities include the entities, material assets (including licenses) and material liabilities owned or possessed by
AiPharma and its subsidiaries as of the date hereof which are set forth on Schedule 4(e) (which may be updated by AiPharma within
seven (7) business days of the date of this Agreement) provided with this Agreement (the “Specified Acquired Assets and Liabilities”).
Prior to the execution of the Definitive Purchase Agreement and as part of the Restructuring, AiPharma shall have the right to transfer
the Specified Acquired Assets and Liabilities among Holdco and Holdco’s subsidiaries in AiPharma’s sole discretion; provided,
that (i) AiPharma shall consult with (and consider in good faith any comment from) Aditxt in connection therewith, (ii) AiPharma will
provide Aditxt with the particulars of the Restructuring and reasonably promptly thereafter Aditxt shall inform AiPharma if such particulars
of the Restructuring will cause adverse tax consequences to Aditxt or any material adverse issues relating to its NASDAQ listing, in which
case AiPharma and Aditxt shall cooperate in good faith to revise the particulars to reduce or eliminate such adverse tax consequences
to Aditxt and such material adverse issues relating to its NASDAQ listing, in each case, to the extent commercially reasonable; and (iii)
at the execution of the Definitive Purchase Agreement all of the Acquired Assets will be directly or indirectly owned by Holdco. In the
event that further restructuring is required by AiPharma after the Initial Closing, the consent of Aditxt shall be required (such consent
not to be unreasonably withheld, conditioned or delayed if such further restructuring shall not adversely affect the ownership (directly
or indirectly) of the Acquired Assets).

 

(f)
Board Appointments. After the execution and delivery of the Definitive Purchase Agreement, Aditxt shall take all actions
necessary to cause two (2) individuals designated by AiPharma to be appointed to the board of directors of Aditxt (each, an “AiPharma
Director”) within fourteen (14) days after the date thereof and shall cooperate and take additional actions as shall be reasonably
necessary in connection therewith; provided, that such individuals meet Aditxt’s customary qualifying requirements (but not,
for the avoidance of doubt, any qualifications relating to “independence”); provided, further, that if any such
individual (or alternate) fails to so qualify, AiPharma shall have the right to designate an alternate individual to be appointed as an
AiPharma Director. Upon any termination of the Definitive Purchase Agreement, AiPharma shall cause the AiPharma Directors to promptly
resign unless otherwise agreed between such AiPharma Director and Aditxt. Such directors, upon appointment, shall deliver to the Board
of Directors of Aditxt an executed resignation letter that will only take effect in the event that the Definitive Purchase Agreement is
terminated.

 

(g)
Financial Statements. Prior to the Initial Closing, the Parties will use commercially reasonable efforts and cooperate for
AiPharma to provide Aditxt the following financial statements: (i) financial statements of AiPharma and its consolidated subsidiaries
(as of the date hereof) prepared under PCAOB standards and audited in accordance with US GAAP as of December 31, 2020 and the interim
period ended June 30, 2021 (including, in each case, audited consolidating schedules), and (ii) unaudited interim financial statements
of AiPharma and its consolidated subsidiaries (as of the date hereof) prepared under PCAOB standards and in accordance with US GAAP for
the interim period ending September 30, 2021 (or such other period as the Parties mutually agree are required for Aditxt’s filings
with the Securities Exchange Commission).

 

5.
Further Assurances. Each Party hereby agrees to take such further actions as may be necessary or reasonably requested by
another Party to give effect to or to achieve the purpose and intent of this Agreement (including the Subsequent Transaction).

 

    6

    

    

 

6.
Notices. All notices, consents, waivers and other communications under this Agreement must be in writing and shall be deemed
to have been duly given: (a) when delivered by hand (with written confirmation of receipt), (b) when transmitted (except if not a business
day, then the next business day) via email to the email address set out below (and sender shall bear the burden of proof of delivery,
which shall be deemed satisfied if such notice is also delivered by hand, deposited in registered or certified mail (postage prepaid,
return receipt requested), or delivered prepaid to a reputable national overnight air courier service on or before the date that is one
(1) business day after its transmission by email), (c) the day following the day (except if not a business day then the next business
day) on which the same has been delivered prepaid to a reputable national overnight air courier service, or (d) the third business day
following the day on which the same is sent by registered or certified mail (postage prepaid, return receipt requested), in each case
to the appropriate addresses set forth below (or to such other addresses as a Party may designate by notice to the other Party):

 

If to AiPharma, to:

 

AiPharma Global Holdings LLC

14th Floor, One JLT,

Jumeirah Lakes Towers

PO Box 103805

Dubai

Attention: xxx

Email: xxxx@aipharmalab.com

 

with a copy (which shall not constitute
notice) to:

 

Greenberg Traurig, LLP

200 Park Avenue

New York, NY 10166

Attention: xxx

Email: xxxx@gtlaw.com

 

If to Aditxt, to:

 

Aditxt, Inc.

737 N. Fifth St., Suite 200

Richmond, VA 23219

Attention: xxx

Email: xxxx@aditxt.com

 

with a copy (which shall not constitute
notice) to:

 

xxx.

Sheppard Mullin Richter & Hampton LLP

30 Rockefeller Plaza

New York, New York 10112

Email: xxxx@sheppardmullin.com

 

7.
Binding Effect. This Agreement shall be binding upon and inure to the sole benefit of the Parties and their respective successors
and permitted assigns, and nothing herein, express or implied, is intended to or shall confer upon any other Person any legal or equitable
benefit, claim, cause of action, remedy or right of any kind.

 

    7

    

    

 

8.
Assignments. Neither this Agreement nor any of the rights, interests or obligations hereunder shall be assigned by any Party
without the prior written consent of the other Party.

 

9.
Amendments and Waivers. This Agreement may only be amended by an instrument in writing signed by both Parties. The Parties
may, to the extent legally allowed, (a) extend the time for the performance of any of the obligations or other acts of the other
Party, (b) waive any inaccuracies in the representations and warranties of the other Party contained herein, or (c) waive compliance
by the other Party with any of the agreements or conditions contained herein. Any agreement on the part of a Party to any such extension
or waiver shall be valid only if set forth in a written instrument signed on behalf of the Party against which such waiver or extension
is to be enforced. Neither the failure nor any delay by any Party in exercising any right, power, or privilege under this Agreement or
the documents referred to in this Agreement will operate as a waiver of such right, power, or privilege, and no single or partial exercise
of any such right, power, or privilege will preclude any other or further exercise of such right, power, or privilege or the exercise
of any other right, power, or privilege. Waiver of any term or condition of this Agreement by a Party shall not be construed as (i) a
waiver by the other Party, (ii) a waiver of any subsequent breach or waiver of the same term or condition by such Party, or (iii) a waiver
of any other term or condition of this Agreement by such Party.

 

10.
No Survival. The Parties, intending to modify any applicable statute of limitations, agree that the representations and
warranties in this Agreement shall terminate effective as of execution of the Definitive Documents, and thereafter, there shall be no
liability on the part of, nor shall any claim be made by, any Party or any of their respective affiliates in respect thereof.

 

11.
Termination; Effect of Termination.

 

(a)
This Agreement may be terminated and the Subsequent Transaction abandoned at any time prior to the execution and delivery of the
Definitive Documents:

 

(i)
by the mutual written consent of the Parties;

 

(ii)
by either Party, if the Definitive Documents have not been executed and delivered by the Parties on or before November 30, 2021
(the “Outside Date”);

 

(iii)
by either Party, if (A) there has been a material breach of or any material failure to perform any covenant or agreement of the
other Party herein (including Section 4(e)), or any representation or warranty of the other Party herein shall be or shall
have become inaccurate in any material respect, and (B) such breach, failure to perform or inaccuracy (1) is not cured by the other
Party prior to the earlier to occur of (x) the Outside Date and (y) the date that is fifteen (15) business days after the delivery
of written notice of such breach, failure to perform or inaccuracy by such Party to the other Party, or (2) is not capable of being cured
by the Outside Date; provided, that the right to terminate this Agreement pursuant to this Section 11(a)(iii) shall not
be available to a Party if such Party is then in material breach of any of its representations, warranties, covenants or agreements contained
in this Agreement;

 

(iv)
by Aditxt, if the circumstances set forth in Schedule 3 hereto are satisfied;

 

(v)
by Aditxt, pursuant to the last sentence of Section 4(b);

 

    8

    

    

 

(vi)
by AiPharma, if Aditxt breaches Section 4(d); or

 

(vii)
by AiPharma, if at any time during the Interim Period, the Initial Aditxt Shares and Secondary Aditxt Shares, collectively, represent
less than 50.1% of the issued and outstanding shares of Aditxt Common Stock as of such time (including, for this purpose, any shares of
Aditxt Common Stock issuable upon the exercise or conversion of any securities issued during the Interim Period, other than any securities
which were issued with the prior written approval of AiPharma).

 

(b)
If this Agreement is terminated pursuant to Section 11(a)(i) or Section 11(a)(ii), then AiPharma shall
make the $4,000,000 contemplated by the Loan Documents (the “$4M Payment”) on November 30, 2021.

 

(c)
If Aditxt terminates this Agreement pursuant to Section 11(a)(iii), then AiPharma shall pay to Aditxt, in cash by wire transfer
of immediately available funds (to an account designated by Aditxt), the $4M Payment under the Loan Documents on November 30, 2021.

 

(d)
If Aditxt terminates this Agreement pursuant to Section 11(a)(iv), then AiPharma shall pay to Aditxt, in cash by wire transfer
of immediately available funds (to an account designated by Aditxt), the $4M Payment under the Loan Documents on November 30, 2021, subject
to any limitations in Schedule 3.

 

(e)
If Aditxt terminates this Agreement pursuant to Section 11(a)(v), then (i) the obligation of AiPharma to make the $4M
Payment shall be terminated and be of no further force or effect, and (ii) Aditxt shall pay to AiPharma, in cash by wire transfer
of immediately available funds (to an account designated by AiPharma), a termination fee equal to $4,000,000 on November 30, 2021.

 

(f)
If AiPharma terminates this Agreement pursuant to Section 11(a)(iii) or Section 11(a)(vi), then (i) the obligation
of AiPharma to make the $4M Payment shall be terminated and be of no further force or effect, and (ii) Aditxt shall pay to AiPharma,
in cash by wire transfer of immediately available funds (to an account designated by AiPharma), a termination fee equal to $4,000,000
on November 30, 2021.

 

(g)
If AiPharma terminates this Agreement pursuant to Section 11(a)(vii), then the obligation of AiPharma to make the $4M
Payment shall be terminated and be of no further force or effect.

 

(h)
Upon the execution and delivery of the Definitive Documents by the Parties, this Agreement shall automatically terminate, and the
Definitive Documents shall supersede this Agreement in its entirety and in all respects as will be provided in the Definitive Documents.
The Parties acknowledge and agree that this Agreement is not the “Definitive Agreement” contemplated by the Loan Documents.

 

(i)
The Parties acknowledge and agree that during the Interim Period, Aditxt will not have any right to require AiPharma to pay the
$4M Payment under any circumstances, except as specifically set forth in this Section 11.

 

12.
Severability. If any provision of this Agreement, or the application thereof to any Person or circumstance is held invalid
or unenforceable, the remainder of this Agreement, and the application of such provision to other Persons or circumstances, shall not
be affected thereby, and to such end, the provisions of this Agreement are agreed to be severable. Upon such determination that any term
or provision is invalid, illegal or incapable of being enforced, the Parties shall negotiate in good faith to replace such provision with
a valid, legal and enforceable provision that corresponds as closely as possible to the intentions of the Parties as expressed so as to
effect the original intent of the Parties as closely as possible in order that the transactions contemplated herein are consummated as
originally contemplated to the fullest extent possible.

 

    9

    

    

 

13.
Choice of Law/Consent to Jurisdiction. All disputes, claims or controversies arising out of or relating to this Agreement,
or the negotiation, validity or performance of this Agreement or the transactions contemplated hereby shall be governed by and construed
in accordance with the laws of the State of Delaware, without regard to its rules of conflict of laws. Each Party hereby irrevocably and
unconditionally (a) consents to submit to the sole and exclusive jurisdiction of the Chancery Court of the State of Delaware for
any Proceeding arising out of or relating to this Agreement or the negotiation, validity or performance of this Agreement or the transactions
contemplated hereby; provided, that if (and only after) such courts determine that they lack subject matter jurisdiction over any
such Proceeding, such Proceeding shall be brought in the Federal courts of the United States located in the State of Delaware (in such
order, the “Chosen Courts”), (b) waives any objection to the laying of venue of any such Proceeding in the Chosen Courts,
and (c) agrees not to plead or claim in any Chosen Court that such Proceeding brought therein has been brought in any inconvenient
forum. Each Party hereby agrees not to commence any such Proceeding other than before the appropriate Chosen Courts. Each Party agrees
that a final, non-appealable judgment in any Proceeding so brought shall be conclusive and may be enforced by suit on the judgment in
any court of competent jurisdiction, or in any other manner provided by law. Each Party agrees that service of summons and complaint or
any other process that might be served in any Proceeding hereunder may be made on such Party by sending or delivering a copy of the process
to such Party to be served at the address of such Party and in the manner provided for the giving of notices in Section 6.
Nothing in this Section 13, however, shall affect the right of any Party to serve legal process in any other manner permitted
by law.

 

14.
Waiver of Jury Trial. EACH OF THE PARTIES HEREBY IRREVOCABLY WAIVES ANY AND ALL RIGHT TO TRIAL BY JURY IN ANY LEGAL PROCEEDING
ARISING OUT OF OR RELATED TO THIS AGREEMENT OR BY THE TRANSACTIONS CONTEMPLATED HEREBY OR THE NEGOTIATION, VALIDITY OR PERFORMANCE HEREOF.

 

15.
Descriptive Headings; Interpretation. The descriptive headings in this Agreement are for convenience of reference only and
will not be deemed to alter or affect the meaning or interpretation of any provision of this Agreement. The Parties are sophisticated
and have been represented by attorneys throughout the transactions contemplated hereby who have carefully negotiated the provisions hereof.
As a consequence, the Parties do not intend that the presumptions of laws or rules relating to the interpretation of contracts against
the drafter of any particular clause should be applied to this Agreement or any agreement or instrument executed in connection herewith,
and therefore waive their effects.

 

16.
Entire Agreement. This Agreement contains the entire agreement of the Parties with respect to the subject matter of this
Agreement and supersedes all previous negotiations, understandings and agreements (whether oral or written) between the Parties relating
to the same.

 

17.
Counterparts. This Agreement may be executed in two or more counterparts, which together shall constitute a single agreement.
Delivery of an executed counterpart of a signature page to this Agreement by pdf or electronic mail intended to preserve the original
graphic and pictorial appearance of the signature shall be effective as delivery of a manually executed original counterpart of this Agreement.

 

[Signature page follows]

 

    10

    

    

 

IN WITNESS WHEREOF, the Parties have executed this
Agreement effective as of the date first above written.

 

	 	AiPharma Global Holdings LLC
	 	 
	 	By: 	/s/ Alessandro Gadotti
	 	 	Name: 	Alessandro Gadotti
	 	 	Title:	 CEO
	 	 
	 	Aditxt, Inc.
	 	 
	 	By:	/s/
    Amro Albanna
	 	 	Name: 	Amro Albanna
	 	 	Title:	 Chief Executive Officer

 

     

    

    

Exhibit
A

 

Material Terms for Subsequent Transaction

 

	Defined Terms	As used herein,
    the following terms shall have the following meanings:
	 	 
	 	“A&R
    Holdco LLC Agreement” means the Amended and Restated Limited Liability Company Agreement of Holdco, to be dated as of the
    date of the Initial Closing (as defined below), to be entered into among Holdco, AiPharma and Aditxt at the Initial Closing.
	 	 
	 	“Holdco”
    means AiPharma Development LLC, a Delaware limited liability company or such other entity designated as part of the Restructuring
    that is a wholly-owned subsidiary of AiPharma and will directly or indirectly hold all of the Acquired Assets at the Initial Closing
    in accordance with Section 4(e) of the Transaction Agreement.
	 	 
	 	“Initial
    Aditxt Shares” means 4,812,995 shares of Aditxt Common Stock (as further described in Schedule 5).
	 	 
	 	“Outstanding
    Loan” means, as of the Initial Closing, all amounts due and owing under the Loan Documents (including, without limitation,
    all principal (including the amount of any Additional Borrowings), accrued and unpaid interest, and any fees or other amounts payable
    in connection with the repayments and cancelation thereof as contemplated by the Definitive Purchase Agreement).
	 	 
	 	“Purchased
    Holdco Interests” means ten percent (10%) of the issued and outstanding equity interests of Holdco.
	 	 
	 	“Subsequent
    Transaction” means the transaction set forth in this Exhibit A.
	 	 
	Subsequent Transaction	Initial
    Closing:
	 	 
	 	Upon (x) the
    execution and delivery of the Definitive Purchase Agreement by the Parties, (y) the completion of the Restructuring by AiPharma and
    (z) any approval from the Committee on Foreign Investment in the United States (“CFIUS”) required to be obtained
    prior to the execution of the Definitive Purchase Agreement, if any (the “Initial Closing”):
	 	 
	 	(i) 	AiPharma shall subscribe
    for and purchase the Initial Aditxt Shares in exchange for the sale of the Purchased Holdco Interests contemplated by clause (ii)
    below and the other consideration contemplated herein, and Aditxt shall sell and issue (in book-entry form) the Initial Aditxt
    Shares to AiPharma.
	 	 
	 	(ii) 	Aditxt shall subscribe
    for and purchase the Purchased Holdco Interests in exchange for the issuance of the Initial Aditxt Shares contemplated by clause
    (i) above and the other consideration contemplated herein, and AiPharma shall sell the Purchased Holdco Interests to Aditxt.

 

    A-1

    

    

 

	 	(iii) 	Aditxt to exchange the
    Outstanding Loan as part of the consideration for the Purchased Holdco Interests. Promptly after the Initial Closing (and in any
    event within (10) business days thereafter), Aditxt will take all actions necessary or desirable to cause the release of all liens
    over the properties and assets of AiPharma and its subsidiaries securing the Outstanding Loan and any and all other obligations under
    the Loan Documents (including, without limitation, providing any releases reasonably necessary or desirable to evidence the satisfaction
    and release of such liens). The Parties will acknowledge and agree that (a) it will be deemed for all purposes that Aditxt paid
    to AiPharma, as partial consideration for the Purchased Holdco Interests, cash in an amount equal to the Outstanding Loan, and, immediately
    after such payment, AiPharma paid such cash to Aditxt in satisfaction of the Outstanding Loan, and (b) upon the deemed repayment
    of the Outstanding Loan pursuant to the terms of this clause (iii), all Loan Documents will be terminated and be of no further
    force or effect, without any further liability thereunder on the part of the Parties and their respective affiliates.
	 	 
	 	(iv)	To the extent the aggregate
    amount of the Additional Borrowings actually made prior to the Initial Closing is less than $8.5 million, then Aditxt shall (a) have
    an obligation to pay to AiPharma an amount equal such difference (the “Loan Shortfall”) prior to the Secondary
    Closing and (b) in furtherance of the foregoing, pay 70% of any and all cash proceeds it receives after the Initial Closing in connection
    with exercises of the Existing Aditxt Warrants to AiPharma until the Loan Shortfall has been paid in full. To the extent Aditxt decides
    to raise additional funds to allow it to pay the Loan Shortfall, Aditxt shall consult with (and consider in good faith any comment
    from) AiPharma in connection therewith. Aditxt’s obligation to pay the Loan Shortfall shall survive any termination of the
    Definitive Purchase Agreement.
	 	 
	 	Additionally,
    at the Initial Closing:
	 	 
	 	(a)	Aditxt to deliver to AiPharma
    (i) a signature page to the A&R Holdco LLC Agreement, duly executed by Aditxt, and (ii) the Initial Aditxt Shares,
    in book entry form; and
	 	 
	 	(b)	AiPharma to deliver to
    Aditxt (i) signature page(s) to the A&R Holdco LLC Agreement, duly executed by Holdco and AiPharma, and (ii) a copy of Exhibit
    A to A&R Holdco LLC Agreement reflecting the transfer of the Purchased Holdco Interests to Aditxt.

 

    A-2

    

    

 

	 	Secondary
    Closing:
	 	 
	 	Two (2) business
    days following the satisfaction or (to the extent permitted by applicable Law) waiver of all of the conditions precedent set forth
    in the Definitive Purchase Agreement (the “Secondary Closing”):
	 	 
	 	(A)	Aditxt to issue to (i)
    AiPharma, (ii) any wholly-owned subsidiary of AiPharma, (iii) any member or related person of AiPharma, (iv) any parent company or
    other holding company of AiPharma, or (v) any combination of the foregoing (in each case, as specified by AiPharma) sufficient shares
    of Aditxt Common Stock (such additional shares, the “Secondary Aditxt Shares”) such that the Initial Aditxt Shares
    and the Secondary Aditxt Shares collectively (the “AiPharma Aditxt Stock”) shall equal 44,714,453 (as further
    described in Schedule 5) in the aggregate (i.e., because the number of Initial Aditxt Shares was equal to 4,812,995, the number
    of Secondary Aditxt Shares will equal 39,901,458).
	 	 
	 	(B) 	AiPharma to transfer all
    the remaining equity interests of Holdco to Aditxt.
	 	 
	 	(C)	AiPharma shall deliver
    agreements by its major holders who may hold directly Aditxt shares after the Closing regarding certain limitations on sales by such
    holders of Aditxt shares (based on the number Aditxt shares they hold, if any) for a period of 6 months after the Closing in the
    form agreed to by the Parties.
	 	 
	Transaction Structure	It is currently
    contemplated that the Subsequent Transaction will be structured as a sale by AiPharma of 100% of the equity interests of Holdco to
    Aditxt in exchange for the Initial Aditxt Shares and the Secondary Aditxt Shares. However, the Parties agree that AiPharma may implement
    the Restructuring (as defined in Section 4(e) of the Transaction Agreement) and change the structure of the Subsequent Transaction
    (and the Definitive Documents shall reflect such structure) as provided in Section 4(e) of the Transaction Document.
	 	 
	Representations and
    Warranties	Parties to
    make representations and warranties in the Definitive Documents (the “R&Ws”) that are customary for transactions
    of this type and reciprocal (other than differences which are necessary as a result of AiPharma being a private company and Aditxt
    being a public company), including, but not limited to, the R&Ws set forth on Exhibit B hereto (which R&Ws shall be
    given by the Parties as of the dates of the respective signing of both the Transaction Agreement and the Definitive Purchase Agreement)
    and in the case of AiPharma shall include the representation in Section 3(i) of the Transaction Agreement.
	 	 
	 	None of the
    Parties’ respective R&Ws will survive the Secondary Closing, and no Party will have any liability for any representations
    or warranties of any person or entity except for fraud, gross negligence or willful malfeasance in connection with making the R&Ws.

 

    A-3

    

    

 

	Covenants	The Definitive
    Documents will have customary covenants (including, with respect to AiPharma, that Holdco will be subject to such covenants), including:
	 	 
	 	 	●	interim operating covenants,
    with (i) customary exceptions for compliance with applicable laws, actions that are expressly required or expressly permitted, COVID-19
    measures, and scheduled items, and (ii) exceptions that are consented to by the other Party, such consent not to be unreasonably
    withheld, conditioned or delayed (and consent will be deemed to be given if no response within three (3) business days);
	 	 
	 	 	●	public announcements;
	 	 
	 	 	●	exclusivity (including,
    with respect to Aditxt’s obligations, a “no shop” provision, and a “fiduciary out”) and;
	 	 
	 	 	●	confidentiality and access
    to information.
	 	 
	 	During the
    period from the Initial Closing to the Secondary Closing or termination of the Definitive Purchase Agreement (if terminated), Aditxt
    shall not issue any securities (which shall not include debt financings in the ordinary course of business) without the prior written
    consent of AiPharma, other than: (i) shares of Aditxt Common Stock pursuant to exercises of Existing Aditxt Warrants; (ii) shares
    of Aditxt Common Stock pursuant to exercises of Existing Aditxt Options; (iii) securities, in the ordinary course of business
    consistent with past practice, pursuant to the Aditxt 2021 Omnibus Equity Incentive Plan and the Aditxt 2017 Equity Incentive Plan,
    as amended as of the date hereof; and (iv) securities to consultants in the ordinary course of business (outside of the foregoing
    plan(s)) up to 500,000 shares of Aditxt Common Stock.
	 	 
	 	The Parties
    will also retain a proxy solicitor to get approval of the Definitive Purchase Agreement and any other matters contemplated thereby
    which requires the consent of the Aditxt stockholders.
	 	 
	 	The Parties
    will also consult with each other on whether to pursue support agreements with any significant stockholders of Aditxt with the goal
    of facilitating the approval by the Aditxt stockholders of the contemplated transactions.
	 	 
	 	None of the
    Parties’ covenants that are to be performed prior to the Secondary Closing will survive the Secondary Closing, and no Party
    will have any liability for any such covenants after the Secondary Closing.
	 	 
	 	The Parties
    will discuss with each other the inclusion in the Definitive Purchase Agreement of appropriate provisions relating to the amendment
    of Aditxt’s certificate of incorporation and bylaws.

 

    A-4

    

    

 

	Consents and Approvals	The only consents/approvals
    which will be required for and constitute conditions to the Secondary Closing of the Subsequent Transaction will include, among others:
	 	 
	 	 	●	HSR (to the extent it is
    determined to be applicable);
	 	 
	 	 	●	CFIUS (to the extent applicable);
	 	 
	 	 	●	the approvals of the stockholders
    of Aditxt of all matters required for the Secondary Closing (the “Stockholder Approvals”); and
	 	 
	 	 	●	NASDAQ – for the
    continued listing of the Aditxt Common Stock after the Secondary Closing, and the listing of the (i) Initial Aditxt Shares (in connection
    with the issuance thereof at the Initial Closing) and (ii) Secondary Aditxt Shares (in connection with the issuance thereof at the
    Secondary Closing).
	 	 
	 	The Parties
    will use their respective commercially reasonable efforts to (i) prepare and submit any required HSR or CFIUS filings and the Nasdaq
    application promptly after signing of the Definitive Documents (and in any event within 10 business days), and (ii) obtain any required
    HSR, CFIUS and Nasdaq approvals as promptly as practicable.
	 	 
	Closing Conditions	The closing
    conditions (in addition to the consents and approvals referenced above) to the Secondary Closing will be, among others, customary
    closing conditions relating to:
	 	 
	 	 	●	No illegality (based on
    law or order);
	 	 
	 	 	●	Bringdown of R&Ws (with
    all R&Ws being subject to a materiality strip and an aggregate MAE standard);
	 	 
	 	 	●	Bringdown of covenants
    (performed in all material respects);
	 	 
	 	 	●	Officer’s certificate
    regarding bringdown of R&Ws and covenants;
	 	 
	 	 	●	No MAE;
	 	 
	 	 	●	Evidence of issuance of
    the Secondary Aditxt Shares;
	 	 
	 	 	●	Listing of the Initial
    Aditxt Shares and Secondary Aditxt Shares on the Nasdaq Stock Market at, and the continuous listing of the Aditxt Common Stock on
    the Nasdaq Stock Market through, the Secondary Closing;
	 	 
	 	 	●	Delivery of interest transfer
    power relating to the Purchased Holdco Interests (no certificate will be delivered), the withdrawal of AiPharma as a member of Holdco
    and the resignations of all managers and officers thereof;
	 	 
	 	 	●	Effectiveness of the S-4
    and or any other documents filed with the SEC; and
	 	 
	 	 	●	Other customary closing
    deliverables.

 

    A-5

    

    

 

	Termination	The Definitive
    Documents will provide for customary termination rights (e.g., mutual agreement, final non-appealable order prohibiting the Subsequent
    Transaction, no closing by agreed end date (with customary extension if any of CFIUS, HSR (if applicable) or Stockholder Approval
    is the only condition that is not satisfied), material breach resulting in failure of rep/covenant closing condition, failure to
    obtain the Stockholder Approval at the Aditxt stockholder meeting).
	 	 
	 	The Definitive
    Purchase Agreement will contain customary “no solicit” and “fiduciary out” provisions.
	 	 
	 	If the Definitive
    Purchase Agreement is terminated under the following circumstances, a termination fee of $3 million will be payable by the person
    specified below:
	 	 
	 	 	●	By the breaching party,
    in the case of a material breach by the breaching party of a representation, warranty, covenant or agreement resulting in a failure
    of a closing condition of such party.
	 	 
	 	 	●	By Aditxt, upon the exercise
    by Aditxt of its “fiduciary out”.
	 	 
	Registration; Registration
    Rights	 	●	Aditxt shall prepare and
    file an S-4/Proxy Statement covering the issuance of the Secondary Aditxt Shares.
	 	 	 
	 	 	●	Aditxt and AiPharma shall
    enter into a Registration Rights Agreement, pursuant to which, among other customary registration rights provided to a significant
    stockholder, AiPharma shall have registration rights that require Aditxt to prepare and file an S-3 Registration Statement (the “Shelf”),
    to be effective no later than three (3) months following the Secondary Closing, to register the resale of the Initial Aditxt Shares
    and Secondary Aditxt Shares issued to and held by AiPharma (or any of its assignees or transferees) (the “Selling Stockholders”).
    The Registration Rights Agreement shall provide for the following, among other customary registration rights to AiPharma:
	 	 
	 	 	o 	that the Shelf shall be
    maintained and kept effective until the Selling Stockholders have sold all of the Initial Aditxt Shares and Secondary Aditxt Shares;
    and
	 	 
	 	 	o  	that the Selling Stockholders
    shall also have registration rights with respect to underwritten offerings and piggyback registration rights.
	 	 
	Post-Closing Governance
    of Aditxt	The Parties
    will in good faith agree on and document in the Definitive Documents the parameters and constitution of Aditxt’s Board of Directors
    from and after the Secondary Closing, taking into account all applicable statutory, regulatory, accounting, and legal requirements,
    the share ownership of Aditxt from and after the Secondary Closing, director qualifications and business needs. Upon such agreement,
    such directors will be nominated by the board of directors following the nominating procedures of Aditxt consistent with past practices;
    provided, that if the 2022 annual meeting occurs prior to the Closing, the board of directors of Aditxt shall implement such
    nominated board from and after the Secondary Closing and recommend such board for election at the next annual stockholders meeting.
	 	 
	Post-Closing Equity
    Incentive Plan	Aditxt shall
    establish a new equity incentive plan providing for the issuance of awards for up to 10 million shares of Aditxt Common Stock.
	 	 
	 	The Parties
    shall negotiate in good faith the key parameters for the equity incentive plan, to be set forth in the Definitive Purchase Agreement.
	 	 
	Employment Agreements	The Parties
    shall agree on the forms of employment agreements and the individuals who will be entering into them, which shall include, but not
    be limited to the executive management teams and key advisors of the consolidated companies.  Such employment agreements
    will be entered into at or prior to the Initial Closing and shall automatically (i) become effective upon the Secondary Closing
    and (ii) terminate upon any termination of the Definitive Purchase Agreement.
	 	 
	Transaction Expenses	Except as noted
    herein, each Party will be responsible for its own customary transaction expenses (e.g., advisors, legal, accounting).

 

    A-6

    

    

Exhibit
B

 

Investment Representations

 

Each Party represents and warrants (solely with respect to itself)
to the other Party as of the date hereof that:

 

		1.	the Party making this representation has been furnished by the other Party with all information regarding
(a) such other Party, and (b) the Securities, and any additional information that it has requested or desired to know, and has been afforded
the opportunity to ask questions of, and receive answers from, duly authorized officers or other representatives of such other Party concerning
the aforementioned. For purposes of this Exhibit B, the term “Securities” shall mean either the Initial Aditxt
Shares or the Purchased Holdco Interests, as applicable;

 

		2.	no Securities were offered or sold to the Party making this representation by means of any form of general
solicitation or general advertising, and in connection therewith, such Party did not (a) receive or review any advertisement, article,
notice or other communication published in a newspaper or magazine or similar media or broadcast over television or radio, whether closed
circuit, or generally available, or (b) attend any seminar meeting or industry investor conference whose attendees were invited by any
general solicitation or general advertising;

 

		3.	the Party making this representation acknowledges that the issuance of the Securities has not been reviewed
by the U.S. Securities and Exchange Commission (the “SEC”) nor any state regulatory authority, and the issuance of
the Securities is intended to be exempt from the registration requirements of the Securities Act of 1933, as amended (“Securities
Act”), pursuant to Section 4(a)(2) thereof and Rule 506 of Regulation D promulgated thereunder. Such Party understands that
the Securities have not been registered under the Securities Act or under any state securities or “blue sky” laws and agrees
not to sell, assign or otherwise transfer or dispose of the Securities unless they are registered under the Securities Act and under any
applicable state securities or “blue sky” laws or unless an exemption from such registration is available;

 

		4.	the Party making this representation consents to the placement of a legend on any certificate or other
document evidencing the Securities that such Securities have not been registered under the Securities Act or any state securities or “blue
sky” laws. Such Party is aware that the issuer of such Securities will make a notation in its appropriate records with respect to
the restrictions on the transferability of such Securities;

 

		5.	the Party making this representation represents that it is an “accredited investor”, as such
term is defined in Rule 501(a) of Regulation D promulgated under the Securities Act; and

 

		6.	the Party making this representation has such knowledge and experience in financial and business matters
that it is capable of evaluating the merits and risks of an investment in the Securities, and it and any accounts for which it is acting
are able to bear the economic risks of and an entire loss of its or their investment in the Securities.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00336-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00336-of-00352.parquet"}]]